Patents by Inventor Peter Sandner

Peter Sandner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240051935
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20230346777
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of ophthalmologic diseases, including non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), retinal ganglion cell/photoreceptor neurodegeneration and cataract.
    Type: Application
    Filed: April 14, 2023
    Publication date: November 2, 2023
    Inventors: William Ernst SCHUBERT, Khaled NASSAR, Peter SANDNER, Carsten TERJUNG, Elia DUH, Hongkwan CHO, Zhenhua XU, Lijuan WU, Lingli ZHOU
  • Publication number: 20230265072
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: April 13, 2023
    Publication date: August 24, 2023
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20230201174
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising finerenone or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and a SGLT2 inhibitor, or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof. The combination can be used for the treatment and/or prevention of cardiovascular and/or renal diseases in humans and other mammals.
    Type: Application
    Filed: April 20, 2021
    Publication date: June 29, 2023
    Inventors: Peter KOLKHOF, Peter SANDNER, Lars BÄRFACKER
  • Patent number: 11684621
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: June 27, 2023
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Kolkhof, Peter Sandner
  • Patent number: 11508483
    Abstract: The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 22, 2022
    Assignee: Adverio Pharma GmbH
    Inventors: Peter Sandner, Melanie Hemmrich, Janethe De Oliveira Pena, Stephen Dawe
  • Patent number: 11439628
    Abstract: The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: September 13, 2022
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Peter Kolkhof, Ilka Mathar, Stefanie Breitenstein
  • Publication number: 20220274958
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: February 8, 2022
    Publication date: September 1, 2022
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20220241273
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of ophthalmologic diseases, including non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), retinal ganglion cell/photoreceptor neurodegeneration and cataract.
    Type: Application
    Filed: February 8, 2022
    Publication date: August 4, 2022
    Inventors: William Ernst SCHUBERT, Khaled NASSAR, Peter SANDNER, Carsten TERJUNG, Elia DUH, Hongkwan CHO, Zhenhua XU, Lijuan WU, Lingli ZHOU
  • Publication number: 20220241255
    Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 4, 2022
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Peter Kolkhof, Peter Sandner
  • Patent number: 11331308
    Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 17, 2022
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Kolkhof, Peter Sandner
  • Publication number: 20220128561
    Abstract: The present invention provides a method for determining whether a human or animal subject suffers from oxidative stress, is suitable of being treated with an antioxidant and/or free radical scavenger, and/or is suitable of being treated with an agonist of soluble Guanylyl Cyclase (sGC), in particular with an activator of sGC, said method comprising the steps of providing a tissue or liquid sample from said subject, and determining whether or not said sample is characterized by the presence, upregulation or overexpression of sGC comprising a heme free ?1 subunit.
    Type: Application
    Filed: January 16, 2020
    Publication date: April 28, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Rene Hoet, Peter Sandner, Jan Robert Krähling, Agnes Benardeau, Ana Lúcia Freitas de Mesquita Barbas, Ligia Nobre, Hugo Soares, Gabriela Silva
  • Publication number: 20210121447
    Abstract: The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).
    Type: Application
    Filed: May 10, 2019
    Publication date: April 29, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Peter Sandner, Peter Kolkhof, Ilka Mathar, Stefanie Breitenstein
  • Publication number: 20210121461
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: December 31, 2020
    Publication date: April 29, 2021
    Inventors: Peter Kolkhof, Peter Sandner
  • Publication number: 20210052528
    Abstract: The present invention relates to sGC activators and sGC stimulators for use in the treatment of cognitive impairment in a mammal in need of such treatment, in particular for use in the treatment of vascular dementia.
    Type: Application
    Filed: April 12, 2019
    Publication date: February 25, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Peter Sandner, Jos Prickaerts
  • Patent number: 10918639
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 16, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Kolkhof, Peter Sandner
  • Publication number: 20190371469
    Abstract: The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.
    Type: Application
    Filed: May 28, 2019
    Publication date: December 5, 2019
    Applicant: ADVERIO PHARMA GMBH
    Inventors: Peter SANDNER, Melanie HEMMRICH, Janethe DE OLIVEIRA PENA, Stephen DAWE
  • Publication number: 20190262340
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: October 5, 2017
    Publication date: August 29, 2019
    Applicant: BAYER PHARAMA AKTIENGESELLSCHAFT
    Inventors: Peter KOLKHOF, Peter SANDNER
  • Publication number: 20190224176
    Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: October 5, 2017
    Publication date: July 25, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter KOLKHOF, Peter SANDNER
  • Patent number: 10265314
    Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 23, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Johannes-Peter Stasch, Michael Hahn, Markus Follmann